Status: Recruiting
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.
Participants needed: 42
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: ToLymph Inc.Updated: Mar 6, 2026Locations: 2
Eligibility criteria
Histopathological confirmed NSCLC [+18]
Evidence of locally advanced T3 or T4 NSCLC or distant metastatic disease. [+8]